HC Wainwright maintains Travere Therapeutics $67 price target
HC Wainwright & Co. maintained its $67.00 per-share price target for Travere Therapeutics, per Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.